Features | Healtcare News | BioTuesdays by Kilmer Lucas IR

This Week's Feature

Avidity Biosciences developing new class of RNA therapeutics

Avidity Biosciences (NASDAQ:RNA) is developing a novel approach for the delivery of RNA therapeutics with a new class, known as antibody oligonucleotide conjugates (AOCs), with an initial focus on skeletal muscle...

December 6, 2022

Feature

Bolt pioneering new approach to cancer immunotherapy

Bolt Biotherapeutics (NASDAQ:BOLT) is developing tumor-targeting therapies that leverage the power of basic components of the innate and adaptive immune systems to attack the tumor microenvironment.

November 29, 2022

Feature

Kinaset developing dry powder inhalation therapy for severe asthma

Closely-held Kinaset Therapeutics is developing a less invasive and potentially more cost-effective dry power inhalation alternative to currently approved injectable biologicals used in the treatment of severe asthma.

November 22, 2022

Feature

MAIA telomere-targeting technology aiming at therapy-resistant tumors

MAIA Biotechnology (NYSE American:MAIA) is developing a telomere-targeting immunotherapy, THIO, with a dual mechanism of action, that can be used in sequential combination with existing immune therapies to target cancer.

November 15, 2022

Feature

Miromatrix bioengineering human organs to eliminate waitlists

With the need for organs for transplantation far exceeding the supply and creating long waitlists, Miromatrix Medical (NASDAQ:MIRO) is bioengineering human organs with the potential to eliminate the transplant waitlists.

November 8, 2022

Feature

Comera working to transform biologics to SQ injections from IV delivery

Comera Life Sciences (NASDAQ:CMRA) is using a proprietary excipient formulation platform, known as SQore, to potentially transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self...

November 1, 2022

Feature

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

With widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, Atossa Therapeutics (NASDAQ:ATOS) has pivoted development of its AT-H201 inhalation therapy to cancer patients with...

October 25, 2022

Feature

OpSens SavvyWire tackling cardiology with advanced optical devices

With last month’s FDA clearance of the SavvyWire transcatheter aortic valve replacement (TAVR) guidewire, OpSens (TSX:OPS; OTCQX:OPSSF) is bringing a new concept to interventional cardiology and the delivery of new...

October 18, 2022

Feature

VoxNeuro is giving the brain a voice through cognitive health assessment

VoxNeuro’s software as a medical device (SaMD) is transforming cognitive health assessment as it pushes the boundaries of our understanding of the brain to improve decision-making by clinicians and patients.

October 11, 2022

Feature

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics (OTCQB:SIGY) has transitioned its Sigyn Therapy blood-purification device from conceptual design two years ago to preparing to initiate its first-in-human studies in end-stage renal disease patients...

October 4, 2022

Feature

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Kiora Pharmaceuticals (NASDAQ:KPRX) expects to release Phase 1b interim data at the beginning of 2023 from its flagship intravitreal injection to potentially restore vision in patients with retinitis pigmentosa, a rare...

September 27, 2022

Feature

Blue Water Vaccines designing vaccines against infectious diseases

Blue Water Vaccines (NASDAQ:BWV) is building an early-stage pipeline of six transformational vaccine candidates targeting important infectious diseases, including inner ear infections, influenza, norovirus, rotavirus...

September 20, 2022

Feature

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

SAB Biotherapeutics (NASDAQ:SABS) is developing its novel DiversitAb platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies, without the need for human donors.

September 13, 2022

Feature

Ensysce Biosciences’ transformative chemistry targeting drug safety and performance

Ensysce Biosciences (NASDAQ:ENSC) is developing next-generation opioid products with its platform of two proprietary technologies to reduce abuse and overdose while relieving suffering for people with severe pain and...

September 6, 2022

Feature

Femasys innovating women’s reproductive health with minimally invasive, in-office technologies

Femasys (NASDAQ:FEMY) is on a road to disrupt traditional approaches to women’s reproductive health with proprietary diagnostics and devices that address global markets in infertility and permanent birth control.

August 30, 2022

Feature

Talking VR and mental health with Foretell Reality

As general manager for Foretell Reality and VP product for parent, Glimpse Group (NASDAQ:VRAR), a company seeking to unlock the benefits of virtual and augmented reality, Dror Goldberg was introduced to VR in its early...

August 23, 2022

Feature

Zymeworks targeting cancer with next-gen multifunctional biotherapeutics

Zymeworks (NYSE:ZYME) is leading a paradigm shift developing next-generation multifunctional antibodies and antibody drug conjugates, with an initial focus on HER2-targeted therapies to treat cancer.

August 16, 2022

Feature

Brickell Biotech pivots to make fresh tracks in autoimmune, inflammatory medicine

After selling its late-stage dermatology program in May 2022, Brickell Biotech (NASDAQ:BBI) has pivoted its focus to developing differentiated therapeutics for the treatment of autoimmune, inflammatory and other...

August 9, 2022

Feature

Rhythm Pharma targeting rare genetic diseases of obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM), with the only FDA-approved therapy that targets a root cause of severe obesity and insatiable hunger, is in clinical development to expand the addressable population of patients...

August 2, 2022

Feature

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Eupraxia Pharmaceuticals (TSX:EPRX) is developing a unique diffusion-based polymer-particle technology initially to provide knee osteoarthritis (OA) patients with an injection in the knee for an extended release of drug...

July 26, 2022

Feature

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

Tonix Pharmaceuticals (NASDAQ:TNXP) is engaged in a number of ongoing and planned clinical trials with a rich pipeline of products, including a Phase 3 clinical trial to treat fibromyalgia, along with a Phase 2 clinical...

July 19, 2022

Feature

TC Biopharm developing gamma-delta T-cells therapies for oncology

TC BioPharm (NASDAQ:TCBP) is a global leader in developing platform allogeneic gamma-delta T-cell therapies for cancer indications, with human efficacy data in acute myeloid leukemia (AML) and plans to expand into other...

July 12, 2022

Avidity Biosciences developing new class of RNA therapeutics

Bolt pioneering new approach to cancer immunotherapy

Kinaset developing dry powder inhalation therapy for severe asthma

MAIA telomere-targeting technology aiming at therapy-resistant tumors

Miromatrix bioengineering human organs to eliminate waitlists

Comera working to transform biologics to SQ injections from IV delivery

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

OpSens SavvyWire tackling cardiology with advanced optical devices

VoxNeuro is giving the brain a voice through cognitive health assessment

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Blue Water Vaccines designing vaccines against infectious diseases

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

Ensysce Biosciences’ transformative chemistry targeting drug safety and performance

Femasys innovating women’s reproductive health with minimally invasive, in-office technologies

Talking VR and mental health with Foretell Reality

Zymeworks targeting cancer with next-gen multifunctional biotherapeutics

Brickell Biotech pivots to make fresh tracks in autoimmune, inflammatory medicine

Rhythm Pharma targeting rare genetic diseases of obesity

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

TC Biopharm developing gamma-delta T-cells therapies for oncology

General

More